

IN THE MATTER OF * BEFORE THE STATE
CHRISTINA M. GETZ, PD * BOARD OF
RESPONDENT * PHARMACY
LICENSE NO.: 16709 * CASE NUMBER: 13-048

* * * * *

ORDER FOR SUMMARY SUSPENSION

Pursuant to Md. State Govt. Code Ann. §10-226 (c) (2009 Repl. Vol.), the State Board of Pharmacy (the "Board") hereby summarily suspends the license of Christina M. Getz, d.o.b. 05/30/1977, License Number: 16709(the "Respondent"), to practice pharmacy under the Maryland Pharmacy Act (the "Act"), Md. Health Occ. Code Ann. ("H. O.") §§12-101 *et seq.* (2009 Repl. Vol.) and Code Md. Regs. tit. 10, § 34.01.12. This Order is based on the following investigative findings, which the Board has reason to believe are true:¹

INVESTIGATIVE FINDINGS

1. At all times relevant hereto, the Respondent was and is licensed to practice pharmacy in the State of Maryland. The Respondent was originally licensed to practice pharmacy in Maryland on or about July 28, 2003.
2. The Respondent's license expires on May 20, 2013.

¹ The statements regarding the Respondent's conduct are only intended to provide the Respondent with notice of the basis for the Board's action. They are not intended as, and do not necessarily represent a complete description of the evidence, either documentary or testimonial, to be offered against the Respondent in this matter.

3. At all times relevant hereto, the Respondent was employed as a pharmacist at Healthcare Facility A.²

4. Healthcare Facility A is a provider of healthcare services located in Alleghany County, Maryland.

5. On or about January 17, 2013, the Board was informed by the Director of Pharmacy Services at Healthcare Facility A that the Respondent had diverted controlled substances from Healthcare Facility A's pharmacy.

6. The Director of Pharmacy Services reported to the Board, that on or about January 11, 2013, the Respondent was caught in possession of approximately eighty (80) Oxycodone 15 mg tablets.

7. The Respondent did not have a prescription for the Oxycodone that was in her possession.

8. The Respondent admitted that she had diverted medication from Healthcare Facility A's pharmacy since November 2009.

9. An investigation by Healthcare Facility A revealed that since March 2012 the Respondent had diverted the following medications:

<u>NAME</u>	<u>QUANTITY</u>
Buprenorphine 8 mg	10 tablets
Oxycodone HCL 15mg	3965 tablets
Oxycodone HCL 5mg	553 tablets
Hydrocodone-APAP 5-500	140 tablets
Hydrocodone-APAP 10-325	1865 tablets

² The name and location of Healthcare Facility A has not been disclosed in order to protect the confidentiality of the involved entity. The name and location of Healthcare Facility is known to the Respondent.

Hydrocodone-APAP 7.5-500	20 tablet
Morphine Sulfate 15 mg	20 tablets
Morphine Sulfate 30 mg	10 tablets
Alprazolam .05 mg	35 tablets
Zolipem Tartrate 10mg	40 tablets
Hyrocodone-Chlorpheniram Susp	50 ml
Chlordiazepoxide 25mg	25 capsules
Modafinil 200 mg	170 tablets
Percocet 5-325 mg	2135 tablets
Hydromorphone 2mg	1028 tablets

10. The Respondent diverted approximately forty-four hundred dollars (\$4400) of medication from Health Facility A.

CONCLUSIONS OF LAW

Based on the foregoing investigative findings, the Board concludes that the public health, safety, and welfare imperatively require emergency action, pursuant to Md. State Gov't. Code Ann. § 10-226(c) (2).

ORDER

Based on the foregoing Investigative Findings and Conclusions of Law, it is this 20TH day of MARCH 2013, by a majority of the Board, hereby:

ORDERED that the license issued to the Respondent to practice as a pharmacist in the State of Maryland under license number: 16709 is hereby **SUMMARILY SUSPENDED**; and it is further

ORDERED that the Respondent is prohibited from practicing as a pharmacist in the State of Maryland; and it is further

ORDERED that the Respondent shall immediately return all licenses to the Board; and it is further

ORDERED that this **ORDER FOR SUMMARY SUSPENSION** is a **PUBLIC DOCUMENT** as defined in Md. State Gov't Code Ann. §§ 10-611 *et seq.* (2009 Repl. Vol. and 2012 Supp.).

MARCH 20, 2013

Date



Michael N. Souranis, P.D.
President
State Board of Pharmacy